Clinical Trial Results:
MERIDIAN: A 12-month prospective, open-label, randomized, multicenter,
parallel-group study to evaluate the efficacy, safety and
tolerability of a Myfortic®-based regimen in the conversion from a
CNI to everolimus in de novo transplant recipients of Expanded
Criteria of Donor kidneys
Summary
|
|
EudraCT number |
2009-018174-54 |
Trial protocol |
SK LV ES CZ |
Global completion date |
15 Jun 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Jan 2017
|
First version publication date |
06 Jan 2017
|
Other versions |
|
Summary report(s) |
CERL080A2423 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.